What is Onesource Specialty Pharma Ltd's market cap?

Onesource Specialty Pharma Ltd (ONESOURCE) has a market capitalization of ₹20,916 Cr.

What sector is ONESOURCE in?

Onesource Specialty Pharma Ltd operates in the Pharmaceuticals — Formulations & API sector.

What is ONESOURCE's return on equity?

Onesource Specialty Pharma Ltd has a return on equity (ROE) of 0.3%.

Loading company...

Analyzing...

Onesource Specialty Pharma Ltd (ONESOURCE) — Analysis, Financials, Intelligence | The Stock Filter

The Organism · Company Intelligence

Onesource Specialty Pharma Ltd

ONESOURCE|BSE: 544292

Pharmaceuticals — Formulations & APIHealthcare & Life Scienceswww.onesourcecdmo.com

—

—|MCap ₹20,916 Cr

Onesource Specialty Pharma Ltd develops and distributes niche pharmaceutical products, catering to specialized therapeutic areas. The company integrates research, regulatory compliance, and supply cha

Secular Currents

Theme Connections

Pharma CDMO Healthcare Access

Intelligence Profile

TSF Score

42/100

The Vitals · Company Health

Health Indicators

Shenanigan Score

55Medium

Trust Score

X-Ray

Concerns

🟠Below-average return on equity (0.3%)Business

Watch

Nothing flagged for monitoring

Strengths

🟢Low leverage (D/E: 0.18x)Business

The Numbers · Key Metrics

ROE

0.3%

Debt/Equity

0.18x

₹20,760 Cr

The Narrator · StoryTel Intelligence

FY2025Pharmaceuticals — Formulations & APIProduct Sales ModelModel:Revenue = Volume of Drugs Sold × Average Selling Price (Domestic + Export)

Key Insight

“Operates in Pharmaceuticals — Formulations & API.”

The Revenue Story

₹1,445 Cr revenue.

Total Income₹1,462 Cr

Revenue₹1,445 Cr(98.8% of Total Income)

Other Income₹17 Cr(1.2% of Total Income)

The Cost Story

COGS 30.1%, employees 14.9%.

EBITDA₹484 Cr(25.4%)

Cogs₹435 Cr(22.9%)

Other Expenses₹328 Cr(17.2%)

Depreciation₹274 Cr(14.4%)

Employee₹215 Cr(11.3%)

Finance Costs₹166 Cr(8.7%)

0.3%EBITDA Margin

EBITDA

25.4%

Cogs

22.9%

Other Expenses

17.2%

Depreciation

14.4%

Employee

11.3%

Finance Costs

8.7%

Key Metrics

ROE

0.3%

vs median 10.5%

ROCE

1.9%

vs median 13.8%

Net Margin

1.4%

vs median 8.7%

EBITDA Margin

27.9%

vs median 16.0%

Debt To Equity

0.18x

vs median 0.21x

Forward View · Management Guidance

GUIDANCEQ3FY26— 3High Impact

“reiterate our FY twenty twenty eight guidance, which we have given of becoming a $400,000,000 revenue company organically.”

GUIDANCEQ3FY26High Impact

“singular guidance that we have provided”

GUIDANCEQ3FY26— 2High Impact

“Firstly, I would like everybody to draw my attention, sorry, draw your attention to my Q4 FY 'twenty five commentary where I highlighted that FY 'twenty six is a transitionary year, where our primary ”

The Context · Where does it sit?

Sector Context

The Canopy · Sector KPIs

Sector KPIs

Pharmaceuticals — Formulations & API

KPI	Company	Sector Median
ROE	0.3%▼	10.5%
ROCE	1.9%▼	13.8%
Net Margin	1.4%▼	8.7%
EBITDA Margin	27.9%▲	16.0%
Debt To Equity	0.18x▼	0.21x

The Market · What is the market saying?

Market Signals

The Antenna · Media Intelligence

Media Signal

Low Impact

The Numbers · Show me the data

Financials

No valuation data

Historical valuation data not available.

Financials

Revenue₹1,419 Cr

PBT(₹8 Cr)

EPS₹1.74

(₹ Cr)	TTM	FY2025
Revenue	₹1,419 Cr -1.8%	₹1,445 Cr
Other Income	₹16 Cr -9.5%	₹17 Cr
Total Income	₹1,435 Cr -1.9%	₹1,462 Cr
COGS	₹412 Cr -5.4%	₹435 Cr
	₹1,433 Cr +1.0%	₹1,419 Cr
Profit Before Tax	(₹8 Cr) +87.8%	(₹67 Cr)
Exceptional Items	(₹10 Cr) +91.0%	(₹111 Cr)
	(₹29 Cr) +42.4%	(₹50 Cr)
Net Profit	₹20 Cr ↑ Recovery	(₹18 Cr)
Profit (Owners)	₹20 Cr ↑ Recovery	(₹18 Cr)
Other Comprehensive Income	₹8 Cr ↑ Recovery	(₹3 Cr)
EPS	₹1.74	(₹1.57)
Diluted Shares	₹11 Cr	₹11 Cr
Profit Loss From Discontinued Operations After Tax	(₹0.69 Cr) 0.0%	(₹0.69 Cr)